Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4685 in advanced solid tumors
NCT07676903Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Aug 2026
- Primary completion
- Oct 2028
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of SHR-4685 in solid tumor, sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 21 days, Maximum Tolerated Dose at 24 months and 3 more. Started Aug 2026; status: recruiting.
02
Drugs
SHR-4685
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07676903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07676903.